Miltefosine, an alkylphospholipid first developed as an anticancer drug, has been shown to have activity against Leis mania species and is a new oral drug for the treatment of visceral leishmaniasis. There is little understanding of the mechanism(s) of action or resistance of this drug in Leis mania. This project will characterise drug targets and resistance mechanisms in L.donovani through molecular/biochemical techniques and chemical structure-activity studies. Results will be used to design strategies to avoid or overcome drug resistance, including drug combinations. Target characterisation will be used as the basis for the identification of further antiprotozoal drugs.
Funding SchemeCSC - Cost-sharing contracts
92290 Chatenay Malabry